Case for caution in expanding attention deficit hyperactivity disorder prescribing.

Max Hankin, Anthony Hew, Shalini Arunogiri, Thileepan Naren

Abstract readReview

In one paragraph

Review in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Max HankinDrug Health Services, Western Health, Footscray, Victoria, Australia.ORCID https://orcid.org/0009-0000-0593-9496

Anthony HewDrug Health Services, Western Health, Footscray, Victoria, Australia.ORCID https://orcid.org/0000-0002-4176-1602

Shalini ArunogiriTurning Point, Eastern Health, Richmond, Victoria, Australia.ORCID https://orcid.org/0000-0002-7667-8868

Thileepan NarenDrug Health Services, Western Health, Footscray, Victoria, Australia.ORCID https://orcid.org/0000-0002-0887-3696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Expanding psychostimulant prescribing to general practitioners (GPs) addresses Australia's attention deficit hyperactivity disorder (ADHD) access crisis, but risks significant unintended consequences. This article highlights the cumulative risks of long-term stimulant use and the danger of fragmented care models. We argue that inconsistent training and the rise of vertically integrated telehealth platforms threaten to reduce ADHD care to a volume-based pharmacological service. To protect public health, Australia requires a national framework prioritising mandatory education, shared care pathways and periodic reviews. Success must be measured by the quality of holistic care, not merely script volume.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsDrug PrescriptionsPractice Patterns, Physicians'AustraliaGeneral PractitionersHumansCentral Nervous System Stimulantsattention deficit hyperactivity disordermodels of careprescribing

Identifiers

PMID42007679

DOI10.1111/imj.70431

PMCPMC13288299

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.